Active Biotech
Research Active Biotech (ACTI.ST) on Bullrun: market cap SEK 136.81M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerACTI.ST
- ExchangeXSTO
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 136.81M
- Financial periodQ1 2026
- RevenueSEK 0
- Net income-SEK 8.40M
- Free cash flow-SEK 8.00M
Valuation Snapshot
latest market cap is SEK 136.81M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 0 | -SEK 37.30M | -SEK 32.40M | n/a | -2.59 | SEK 65.10M | SEK 1.74M | SEK 55.61M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-16 | SEK 136.81M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Active Biotech
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Active Biotech's market cap?
Active Biotech's market capitalization is SEK 136.81M.
What does Active Biotech do?
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors.